clinsight

Press release

Clinsight closes investment round to take its AI prostate cancer diagnostics to CE-IVDR certification

Stockholm, 16 November 2026 – Clinsight AB, a Karolinska Institutet spin-out developing AI-based digital pathology for prostate cancer, today announced the closing of a financing round led by Trio Impact Invest, with participation from two additional investors.

The financing takes Clinsight from validated science to a certified clinical product. It funds the implementation of an ISO 13485 quality management system and the submission of technical documentation to a Notified Body for CE-IVDR certification of the ClinAI platform.

ClinAI analyse biopsies already processed in routine prostate cancer diagnostics to support diagnosis and predict how the disease is likely to progress. It is designed to help clinicians decide which men can safely remain on active surveillance and which need more intensive treatment. The platform was developed at Karolinska Institutet and validated against long-term clinical outcomes. Prostate cancer is the second most commonly diagnosed cancer in men worldwide, with 1.4 million new cases per year.

“Prostate cancer is one of the most overtreated and undertreated cancers at the same time,” said Stefan Almestrand, Chairman and co-founder of Clinsight. “This round lets us turn more than a decade of Karolinska Institutet research into a certified product that helps clinicians understand how the disease is likely to progress and make better-informed treatment decisions at diagnosis. Our investors’ backing takes us all the way to certification and first clinical use.”

“We generally don’t invest in AI tools; it is one of the most crowded segments in venture today. Clinsight changed our view. Its models are trained on proprietary pathology data collected over many years, a dataset that is hard to replicate and cannot be accelerated with capital alone. In effect, the tool captures the diagnostic judgement of a large group of experienced clinicians. That, combined with a team with recognised thought leadership and a proven ability to execute, turned what began as a concern into an opportunity,” said Siimon Vaske, CEO and Fund Manager, Trio Impact Invest.

About Clinsight

Clinsight AB is a Karolinska Institutet spin-out, founded in 2022, developing AI-powered digital pathology for prostate cancer. Its ClinAI platform predicts disease outcome and supports diagnosis from routine biopsy slides, and is offered to healthcare providers and pharmaceutical sponsors as a software service. clinsight.net

About Trio Impact Invest

Trio Impact Invest is a deeptech venture capital investor backing research-intensive companies with scientifically proven technology that addresses societal challenges. The fund was initiated by the venture arms of KTH Royal Institute of Technology, Karolinska Institutet and Stockholm University, and builds on their experience of commercialising research since 1997. The fund is financed by private capital and co-financed by the European Regional Development Fund through Tillväxtverket. www.tii.vc

Media contact

Info@clinsight.net